The Correlation between Metabolic Syndrome and Prostatic Growth in Patients with Benign Prostatic Hyperplasia

European Urology

Volumn 51, Issue 1, 2007, Pages 199-206

  Ozden, Cuneyt ^a   Ozdal, Ozdem Levent ^a   Urgancioglu, Guvenc ^a   Koyuncu, Hakan ^a   Gokkaya, Serkan ^a   Memis, Ali ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Benign prostatic hyperplasia; Hyperinsulinemia; Metabolic syndrome

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY HEIGHT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; EVALUATION; GLUCOSE BLOOD LEVEL; HIP; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; TUMOR GROWTH; WAIST CIRCUMFERENCE;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; HUMANS; INSULIN; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA;

EID: 33751414540     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.05.040     Document Type: Article

References (32)

1. Berry S.J., Coffey D.S., Walsh P.C., and Ewing L.L. The development of human benign prostatic hyperplasia with age. J Urol 132 (1984) 474-479
2. Holtgrewe H.L. Economic issues and the management of benign prostatic hyperplasia. Urology 46 (1995) 23-25
3. Madersbacher S., Alivizatos G., Nordling J., Sanz C.R., Emberton M., and de la Rosette J.J. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46 (2004) 547-554
4. Lee C., Kozlowski J.M., and Grayhack J.T. Etiology of benign prostatic hyperplasia. Urol Clin North Am 22 (1995) 237-246
5. Dahle S.E., Chokkalingam A.P., Gao Y.T., Deng J., Stanczyk F.Z., and Hsing A.W. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 168 (2002) 599-604
6. Hammarsten J., and Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39 (2001) 151-158
7. Ziada A., Rosenblum M., and Crawford E.D. Benign prostatic hyperplasia: an overview. Urology 53 (1999) 1-6
8. Hammarsten J., and Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 8 (1999) 29-36
9. Krotkiewski M. Role of muscle capillarization and morphology in the development of insulin resistance and metabolic syndrome. Presse Med 23 (1994) 1353-1356
10. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
11. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 16 (2002) 356-359
12. Christensen M.M., and Bruskewitz R.C. Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention. Urol Clin North Am 17 (1990) 509-516
13. Guess H.A. Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 14 (1992) 131-153
14. Giovannucci E., Rimm E.B., Chute C.G., et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol 140 (1994) 989-1002
15. Bourke J.B., and Griffin J.P. Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. Br J Urol 38 (1966) 18-23
16. Hammarsten J., Hogstedt B., Holthuis N., and Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1 (1998) 157-162
17. Hammarsten J., and Hogstedt B. Calculated fast-growing benign prostatic hyperplasia-a risk factor for developing clinical prostate cancer. Scand J Urol Nephrol 36 (2002) 330-338
18. Hammarsten J., and Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 13 (2004) 47-55
19. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 61 (1986) 1081-1090
20. James S., Chapple C.R., Phillips M.I., et al. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate. J Urol 142 (1989) 438-444
21. Shieh S.M., Sheu W.H., Shen D.C., Fuh M.M., Chen Y.D., and Reaven G.M. Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. Am J Hypertens 5 (1992) 827-831
22. McVary K.T. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 47 (2005) 838-845
23. Peehl D.M., Cohen P., and Rosenfeld R.G. The role of insulin-like growth factors in prostate biology. J Androl 17 (1996) 2-4
24. Torring N., Vinter-Jensen L., Pedersen S.B., Sorensen F.B., Flyvbjerg A., and Nexo E. Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate. J Urol 158 (1997) 222-227
25. Colao A., Marzullo P., Spiezia S., et al. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. J Clin Endocrinol Metab 84 (1999) 1986-1991
26. Ketelslegers J.M., Maiter D., Maes M., Underwood L.E., and Thissen J.P. Nutritional regulation of the growth hormone and insulin-like growth factor-binding proteins. Horm Res 45 (1996) 252-257
27. Nyomba B.L., Berard L., and Murphy L.J. Free insulin-like growth factor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity. J Clin Endocrinol Metab 82 (1997) 2177-2181
28. Kalkhoff R.K., and Kim H.J. Metabolic responses to fasting and ethanol infusion in obese, diabetic subjects. Relationship to insulin deficiency. Diabetes 22 (1973) 372-380
29. Bjorntorp P., De Jounge K., Sjostrom L., and Sullivan L. The effect of physical training on insulin production in obesity. Metabolism 19 (1970) 631-638
30. Nilsson P.M., Lindholm L.H., and Schersten B.F. Life style changes improve insulin resistance in hyperinsulinaemic subjects: a one-year intervention study of hypertensives and normotensives in Dalby. J Hypertens 10 (1992) 1071-1078
31. Landin K., Tengborn L., and Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 229 (1991) 181-187
32. Pollare T., Lithell H., and Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321 (1989) 868-873